Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Overview of attention for article published in The Lancet, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 58 news outlets
blogs: 6 blogs
policy: 1 policy source
twitter: 1174 X users
patent: 1 patent

facebook: 12 Facebook pages
reddit: 3 Redditors
guideline: 1 clinical guideline source
bluesky: 5 Bluesky users

Readers on

mendeley: 572 Mendeley

So far, Altmetric has seen 7 posts from 6 blogs.

HPV-Impfung: was sind die Fakten?

Medizin transparent, 20 Mar 2019

>Die HPV-Impfung senkt das Risiko für Vorstufen von Gebärmutterhalskrebs. Wahrscheinlich schützt die Impfung langfristig auch…

HPV-Impfung: was sind die Fakten?

Medizin transparent, 20 Mar 2019

Die HPV-Impfung senkt das Risiko für Vorstufen von Gebärmutterhalskrebs. Wahrscheinlich schützt die Impfung langfristig auch…

The silver bullet that saves women

Forum:Blog, 06 Aug 2018

90% of cervical cancers worldwide could be prevented simply by vaccinating young girls. Yet more countries celebrate Mother’s…

Australia to cut cervical cancer risk with less regular tests

One Per Cent, 01 Nov 2017

From 1 December, instead of the 2-yearly Pap smear – also known as a Pap test or smear test – Australian women will have a 5-year…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 3 additional blog posts.